Treatment with Nerivio, an FDA-approved remote electrical neuromodulation device, may be more effective than standard of care medications in adolescents with migraine, according to findings from a post-hoc analysis.

Nerivio is a wireless remote electrical neuromodulation device approved for the acute treatment of episodic or chronic migraine in patients 12 years of age and older. The device is self-applied to the upper arm and uses electrical pulses to stimulate C and Aδ nociceptive sensory fibers to activate the brain’s conditioned pain modulation response to treat pain and migraine symptoms. 

The 2-month comparison analysis included 35 patients between 12 to 17 years of age with chronic and episodic migraines. Pain freedom and pain relief outcomes were compared between a run-in phase in which migraine attacks were treated with oral triptans and over the counter medications for 1 month, and an intervention phase in which attacks were treated with Nerivio for 1 month. Efficacy was assessed using McNemar’s test 2 hours post treatment. 

Continue Reading

Results demonstrated that at 2 hours post treatment, 37.1% of patients treated with Nerivio achieved pain freedom compared with 8.6% of patients treated with standard of care (P =.004). Additionally, a larger proportion of patients treated with Nerivio achieved pain relief compared with those receiving medications (71.4% vs 57.1%; P =.225).

Consistency of pain freedom and pain relief (defined as response in ³50% of the available first 4 treatments), were achieved by 40% and 80% of Nerivio-treated patients, respectively, compared with 8.6% (P <.001) and 57.2% (P =.033) of those receiving standard of care.

“To my knowledge, this is the first study that directly compared remote electrical neuromodulation and standard care treatment options in adolescents,” said Andrew D. Hershey, MD, PhD, co-director of the Headache Center and the endowed chair and director of the Division of Neurology at Cincinnati Children’s Hospital Medical Center, who was the primary investigator in the study, and lead author of the article. “Providing teens with more effective and engaging treatments for migraine can have far-reaching positive effects over the course of their lives.”


  1. Study compares Nerivio® to standard care medications for acute treatment of migraine in adolescents. [press release]. Netanya, Israel and Montclair, NJ: Theranica; June 30, 2021. 
  2. Hershey AD, Irwin S, Rabany L, et al. Comparison of remote electrical neuromodulation (REN) and standard-care medications for acute treatment of migraine in adolescents: a post-hoc analysis. Pain Medicine. Published online June 29, 2021. doi: 10.1093/pm/pnab197

This article originally appeared on MPR